Watch for Andexxa, a New Anticoagulant Reversal Agent
July 2018
Andexxa (an-DEK-sah, inactivated recombinant factor Xa) will be a new, IV direct oral anticoagulant (DOAC) reversal agent.
Until now, the only reversal agent for the DOACs was Praxbind (idarucizumab). But it only inactivates Pradaxa (dabigatran)...a direct thrombin inhibitor.
Andexxa will be bigger news...it's an antidote for two factor Xa inhibitors, Eliquis (apixaban) or Xarelto (rivaroxaban).
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote